Navigation Links
Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
Date:5/7/2008

osts related to the Phase 3 clinical program for lorcaserin hydrochloride, Arena's drug candidate for the treatment of obesity. Research and development expenses included $1.0 million in non-cash, share-based compensation expense in each of the quarters ended March 31, 2008 and 2007. General and administrative expenses totaled $8.9 million in the first quarter of 2008, compared to $4.9 million in the first quarter of 2007. This increase in general and administrative expenses is primarily attributable to increases in patent costs and personnel-related expenses. Total patent costs, including patent costs related to partnered programs, increased by $1.7 million in the first quarter of 2008 compared to the first quarter of 2007. General and administrative expenses in the first quarter of 2008 included $1.4 million in non-cash, share-based compensation expense, compared to $0.9 million in the first quarter of 2007.

Cash, cash equivalents and short-term investments totaled $333.6 million at March 31, 2008. Approximately 73.8 million shares of common stock were outstanding at March 31, 2008.

Arena's First Quarter Highlights

o Initiated a Phase 2b clinical trial of APD125, an oral drug candidate

intended to reduce insomnia symptoms and improve sleep maintenance and

quality. This Phase 2b trial is a double-blind, randomized,

placebo-controlled subjective study that is expected to enroll

approximately 675 patients in about 70 clinical sites in the United

States.

o Reported that, following a planned review by an independent

Echocardiographic Safety Monitoring Board, or ESMB, Arena is continuing

BLOOM, a pivotal clinical trial evaluating the efficacy and safety of

lorcaserin for the treatment of obesity. The ESMB's review of unblinded

echocardiographic data performed after all patients had the opportunity

to complete 12 months of dosing in the trial confirmed that d
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014 Lawrence Livermore scientists Charles Westbrook ... list of " The World's Most Influential Scientific Minds ... 3,000 researchers who were identified by analyzing citation data ... published the highest-impact work (2002-2012 and 2012-2013). The two ... combustion modeling . , "This recognition is a great ...
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- Xybion Corporation, ... for global corporations operating in highly regulated industries, ... first annual Global User Group Conference, Xybion International ... Philadelphia, Pennsylvania at the Sheraton ... http://photos.prnewswire.com/prnh/20140724/130263 This year,s conference ...
(Date:7/25/2014)... July 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... June 30, 2014, after market close on Thursday, August 14, ... to the market opening on Friday, August 15, 2014, at ... China Standard Time) to review the Company,s financial results and ...
(Date:7/24/2014)... -- A novel combination of microscopy and data processing ... Ridge National Laboratory an unprecedented look at the surface ... electrochemical properties. , The research team led by ... of a perovskite manganite, a complex material that exhibits ... understand surface behavior could benefit researchers who are interested ...
Breaking Biology Technology:Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2ORNL study reveals new characteristics of complex oxide surfaces 2
... MOORESVILLE, N.C., Sept. 22 Anpath Group, Inc. (OTC Bulletin ... Inc. (ESI) has made steady progress in the Japanese market ... Minntech Japan is a division of Minntech Corporation, ESI,s manufacturing ... Japan relationship in November 2008 and has since reported the ...
... , , THOUSAND OAKS, Calif., ... announced detailed results from a Phase 3, head-to-head trial evaluating ... metastases in 2,046 patients with advanced breast cancer that met ... to Zometa. These results were presented today during the Presidential ...
... ... answer the question, "Is the Jatropha sector becoming a DotCom Bubble?". 2nd JatrophaWorld ... Viridesco Ltd. will discuss the challenges, controversies & paradoxes of the nascent Jatropha non-food ... ...
Cached Biology Technology:Anpath Group, Inc. Reports Progress in Japanese Market 2Anpath Group, Inc. Reports Progress in Japanese Market 3Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 2Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 3Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 4Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 5Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 6Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 7Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 8Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 9Will Jatropha Become a 'DotCom Bubble' in Biofuel Industry? Leading to 2nd JatrophaWorld Africa, Jatropha Webinar on 30 Sept 09 Explores Challenges & Offers Strategies for Long-Term Success for This Non-Food Crop for Fuel 2
(Date:7/24/2014)... planet,s current biodiversity, the product of 3.5 billion years ... the history of life. But it may be reaching ... scientific literature and analysis of data published in ... the loss and decline of animals is contributing to ... planet,s sixth mass biological extinction event. , Since 1500, ...
(Date:7/24/2014)... A multi-institutional team of researchers has developed a new ... safe, noninvasive method for assessing the function and properties ... to better diagnosis and treatment of gut diseases. ... irritable bowel syndrome and inflammatory bowel disease all occur ... effects in patients with diseases such as diabetes and ...
(Date:7/24/2014)... have similar counterparts in humans, affect the connections between ... into the hippocampus, an area of the brain that ... creation of memories. The results of the study have ... Brain function depends on the active communication between nerve ... woven together into a dense network where they constantly ...
Breaking Biology News(10 mins):Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3New imaging agent provides better picture of the gut 2A protein couple controls flow of information into the brain's memory center 2A protein couple controls flow of information into the brain's memory center 3A protein couple controls flow of information into the brain's memory center 4
... When your body cranks up the heat, its a ... help fight off the infection. But turning up the ... in 25 infants or small children, high fever can ... generally harmless, a prolonged fever resulting from infection or ...
... to chase down speeding vehicles as the movie Jurassic Park ... was certainly no slouch, research out today suggests. The ... the running speeds of five meat-eating dinosaurs that varied in ... The study believed to be the most accurate ever ...
... since the Manhattan project in World War II, ... technology. Yet,scientists still seek the ability to interpret ... and materials using first principle theory. Computational actinide ... PNNL scientist Jun Li will provide an overview ...
Cached Biology News:Feeling hot, hot, hot: New study suggests ways to control fever-induced seizures 2T. rex quicker than Becks, say scientists 2
Ultra-sensitive, non-radioactive detection of Protein G. Measure Protein G levels quickly and easily....
Request Info...
TRIS-EDTA based buffer prepared from RNase-free water suitable for storage and dilution of siRNA, pH 8, store at 4 C ...
Request Info...
Biology Products: